Cryo-Cell International, Inc. (CCEL) Stock Score, Valuation & Financial Research
Cryo-Cell International, Inc. is in the Healthcare sector and Medical - Care Facilities industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 24/100.
Quick answer for CCEL
Cryo-Cell International, Inc. currently has a Wall Street Score of 24/100. The stored market price is $4.41. Its financial score is 32/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Cryo-Cell International, Inc. does
Cryo-Cell International, Inc. engages in cord blood and cord tissue cryopreservation services in the United States. The company offers cellular processing and cryogenic storage for family use, primarily for collection and preservation of umbilical cord blood, and tissue stem cells; and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. It is also involved in the manufacturing of PrepaCyte CB processing system units for processing umbilical cord blood stem cells. In addition, the company provides cold storage services to third-party pharmaceutical companies and medical institutions. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. The company
CCEL financial snapshot
- Wall Street Score:
- 24/100
- Current price:
- $4.41
- Market capitalization:
- $35.6M
- Revenue:
- $31.1M
- Net income:
- $-2.5M
- Free cash flow:
- $5.2M
- Cash:
- $507K
- Total debt:
- $9.0M
- EPS:
- -0.29
- Financial score:
- 32/100
- Valuation score:
- 0/100
- Revenue score:
- 9/100
What stands out
- Reported year-over-year revenue growth is -0.0%.
- Free cash flow is $5.2M, showing positive cash generation.
- The balance sheet shows $507K of cash versus $9.0M of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 32/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-14.
How to research CCEL
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.